NCT00565058 - Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

February 28, 2010

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL

GTI-2040

GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC

Trial Locations (7)

10029

The Mount Sinai Hospital, New York

14263

Roswell Park Cancer Institute, Buffalo

30342

Northside Hospital, Atlanta

46202

Indiana Cancer Research Institute, Indianapolis

94121

San Francisco Veterans Affairs Medical Center, San Francisco

UCSF Medical Center, San Francisco

43210-1240

The Ohio State University, Columbus